Coriell Forms New PGx Advisory Group; FDA Genomics Head Zineh Appointed Chair

In a January 20, 2010, GenomeWeb article, editor Turna Ray reports on Coriell’s establishment of a Pharmacogenomics Advisory Group as part of the Coriell Personalized Medicine Collaborative® (CPMC®) research study.

The goal of this group is to advise the study team as to which gene-drug pairs are potentially actionable. Issam Zineh, PharmD, M.P.H., Associate Director for Genomics at the Office of Clinical Pharmacology in the FDA’s Center for Drug Evaluation and Research, has been named as the group’s chair.

“With Zineh as head of CPMC's PGx advisory group, the FDA can also learn more about the prevalence of specific drug response genes within the CPMC's diverse study cohort,” reports Ms. Ray. “Lawrence Lesko, director of the Office of Clinical Pharmacology at FDA's CDER, has previously indicated the agency's interest in collaborating with entities working in the consumer genomics space to track adverse drug reactions in the post-market setting.”

To read the article in its entirety, visit GenomeWeb’s website: http://www.genomeweb.com/dxpgx/coriell-forms-new-pgx-advisory-group-fda-genomics-head-zineh-appointed-chair?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+genomeweb+%28GenomeWeb+%C3%9Cberfeed%29.